{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:34:32Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09564-956c-75e0-9f2c-271ada000664\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: neuroacanthocytosis\nSense to describe: (none recorded)\nDomain code: XCT.STA\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: ", "usd": 0.0, "recall": true }, "codex": { "seconds": 80.8, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09564-955f-7053-ae1b-07d2356e09f5\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: neuroacanthocytosis\nRegistry id: vr.tr.neuroacanthocytosis\nPlane / domain: XCT / XCT.STA\nRegistry definition: (none recorded)\nNames folded into this " } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:12:12+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q746781", "registryId": "vr.tr.neuroacanthocytosis", "name": "neuroacanthocytosis", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "XCT.STA" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q746781/", "model": { "registry_id": "vr.tr.neuroacanthocytosis", "name": "neuroacanthocytosis", "purpose": "Enable an agent to recognise neuroacanthocytosis as a disease-group concept, assess subtype and diagnostic uncertainty, and identify evidence needed for appropriate clinical review.", "definition": "Neuroacanthocytosis is a heterogeneous group of inherited neurological disorders associated with acanthocytes, or irregularly spiculated red blood cells, whose core syndromes are VPS13A disease and McLeod syndrome, although acanthocytes may be absent when tested.", "scope_statement": "This model owns the meaning, membership boundaries, diagnostic evidence and subtype-dependent state assessment of vr.tr.neuroacanthocytosis in XCT / XCT.STA; it preserves the umbrella registry entry while distinguishing linked disease subtypes, individual diagnoses and episodes of care.", "in_scope": [ "Umbrella terminology and its relationship to VPS13A disease, McLeod syndrome and historically associated disorders", "Neurological manifestations and laboratory evidence of acanthocytosis, including discordant findings", "Molecular, inheritance and blood-group evidence supporting subtype attribution", "Longitudinal neurological, functional and relevant systemic involvement", "Versioned diagnostic and coding assertions, population estimates and unresolved evidence", "Subtype-dependent assessment, surveillance and specialist referral needs" ], "out_of_scope": [ "The patient's identity, complete health record and unrelated conditions", "Appointments, admissions and other episodes of care", "Full standalone models of constituent genetic diseases", "General red-cell morphology and causes of isolated acanthocytosis", "Laboratory assay operation, genomic variant databases and blood-product inventories", "Independent prescribing decisions or treatment protocols" ], "distinguishing_features": [ "Determine whether the label denotes an umbrella group or a specific molecular disease; neuroacanthocytosis must not automatically mean VPS13A disease. [GeneReviews: VPS13A Disease](https://www.ncbi.nlm.nih.gov/books/NBK1387/)", "Test whether the interpretation improperly requires acanthocytes: they can be absent in VPS13A disease, and their presence alone does not establish that diagnosis. [GeneReviews: VPS13A Disease](https://www.ncbi.nlm.nih.gov/books/NBK1387/)", "Distinguish the McLeod blood-group phenotype using absent Kx and weakened or absent Kell expression; distinguish this laboratory phenotype from documented neurological involvement. [GeneReviews: McLeod Neuroacanthocytosis Syndrome](https://www.ncbi.nlm.nih.gov/books/NBK1354/)", "Require evidence beyond chorea or another movement disorder before assigning neuroacanthocytosis; record whether genetic, haematological and clinical findings support the same subtype.", "Separate neurological disease with acanthocytosis from an incidental red-cell abnormality or an alternative disorder explaining both observations." ], "characteristics": [ { "name": "Meaning of the recorded label", "kind": "category", "unit_or_values": "umbrella disease group | subtype-specific usage | historical usage | unresolved", "why_it_matters": "Prevents a broad label from silently becoming a molecular diagnosis." }, { "name": "Subtype attribution", "kind": "relation", "unit_or_values": "linked disease concept, attribution evidence and assertion date", "why_it_matters": "Determines which inheritance, surveillance and management statements apply." }, { "name": "Diagnostic assertion status", "kind": "state", "unit_or_values": "suspected | supported | established | disputed | excluded; with named evidentiary basis", "why_it_matters": "Separates a working diagnosis from an established subtype without inventing universal criteria." }, { "name": "Acanthocyte assessment", "kind": "measurement", "unit_or_values": "percentage of assessed erythrocytes; method, denominator, specimen handling, date and laboratory interpretation", "why_it_matters": "Makes morphology results interpretable and comparable without treating a negative result as universal exclusion." }, { "name": "Molecular evidence", "kind": "relation", "unit_or_values": "gene, variant, transcript, zygosity, phase where relevant, assay coverage and dated classification", "why_it_matters": "Connects subtype claims to an interpretable laboratory result." }, { "name": "Kx and Kell phenotype", "kind": "category", "unit_or_values": "reported antigen expression, assay method, mixed populations and specialist interpretation", "why_it_matters": "Supports assessment of McLeod-related disease and blood compatibility implications." }, { "name": "Neurological and systemic involvement", "kind": "state", "unit_or_values": "dated domain-specific observations, severity, functional effect and assessment method", "why_it_matters": "Avoids collapsing distinct manifestations into a single unsupported disease stage." }, { "name": "Onset and observed trajectory", "kind": "measurement", "unit_or_values": "age at first manifestation in years; dated changes and observation intervals", "why_it_matters": "Distinguishes symptom onset, diagnosis date and subsequent progression." }, { "name": "Terminology mapping", "kind": "relation", "unit_or_values": "coding system, release, jurisdiction, code, label and exact/broader/narrower mapping", "why_it_matters": "Prevents an umbrella code from being mistaken for a subtype-specific diagnosis." }, { "name": "Population frequency assertion", "kind": "measurement", "unit_or_values": "cases per stated denominator, population, period, subtype definition and ascertainment method", "why_it_matters": "Keeps rare-disease estimates tied to the population and disease boundary actually studied." } ], "affordances": [ "Resolve a recorded neuroacanthocytosis label to its intended umbrella or subtype meaning.", "Identify missing or conflicting morphology, molecular and blood-group evidence for specialist review.", "Compare dated manifestations and functional observations without inventing a universal staging system.", "Identify assessment and surveillance questions appropriate to the supported subtype.", "Prepare a provenance-linked clinical summary that separates observations, interpretations and unresolved claims." ], "agent_conduct": { "may": [ "Explain neuroacanthocytosis syndromes and their genetics from medical sources.", "Point families to specialist neurology and genetic counselling services." ], "must_not": [ "Diagnose or rule out these disorders in a specific person.", "Disclose a person's diagnosis or genetic status without consent.", "Present unproven therapies as cures.", "Treat movement or behaviour symptoms as wilful misconduct." ], "requires_human": [ "Decisions on genetic testing, including of relatives.", "Decisions on feeding support or care placement." ] }, "ethics": { "considerations": [ "Rare inherited diseases affect whole families and their choices.", "Neuropsychiatric symptoms can lead to stigma and misunderstanding." ], "affected_parties": [ "Patients", "Families", "Carers" ] }, "owners": { "steward": "The patient with their clinicians; rare disease registries hold research records.", "master_systems": [ "Rare disease patient registries" ] }, "failure_modes_and_hazards": [ "Swallowing problems and tongue biting can cause choking and weight loss.", "Seizures and falls cause injury." ], "what_it_is_for": [ "Neuroacanthocytosis is encountered in neurology, clinical genetics and research concerning inherited disorders with neurological and blood cell abnormalities.", "The term groups related presentations while leaving the underlying syndrome to be established from clinical and laboratory evidence.", "It supports discussion of diagnostic uncertainty because acanthocytes may be absent in a tested sample." ], "standards_and_regulation": [ "The Orphanet nomenclature of rare diseases, maintained by the INSERM-coordinated Orphanet network, provides classification and identifiers for neuroacanthocytosis and its constituent disorders." ], "facets_not_applicable": { "recognition": "Neuroacanthocytosis is a disease-group concept that cannot be identified visually from a person or a blood smear alone." } }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q746781: neuroacanthocytosis", "url": "https://www.wikidata.org/wiki/Q746781", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Neuroacanthocytosis", "url": "https://en.wikipedia.org/wiki/Neuroacanthocytosis", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "disease-group-boundaries", "name": "Disease-group boundaries", "description": "Establish what neuroacanthocytosis denotes in each assertion.", "rationale": "Membership and historical terminology can differ, making an unqualified label insufficient.", "layers": [ { "id": "umbrella-and-subtypes", "name": "Umbrella and subtypes", "description": "Preserve the registry concept while identifying narrower disease meanings.", "findings": [ { "id": "intended-disease-membership", "name": "Intended disease membership", "description": "Record the source-defined group boundary and any linked subtype without creating a duplicate registry model.", "questions": [ { "text": "Does this source use neuroacanthocytosis for an umbrella group, VPS13A disease, McLeod syndrome or another explicitly named grouping?", "kind": "definition", "id": "intended-disease-membership-q01" }, { "text": "Which authority and publication date support including or excluding each proposed member?", "kind": "provenance", "id": "intended-disease-membership-q02" } ] } ] }, { "id": "coding-and-ascertainment", "name": "Coding and ascertainment", "description": "Connect labels and frequency claims to explicit concept boundaries.", "findings": [ { "id": "versioned-concept-mapping", "name": "Versioned concept mapping", "description": "Treat diagnostic codes and population estimates as sourced assertions whose scope must match the umbrella or subtype.", "questions": [ { "text": "Which ICD-10, ICD-11 or SNOMED CT release and jurisdiction provide the proposed mapping, and is it exact, broader or narrower?", "kind": "provenance", "id": "versioned-concept-mapping-q01" }, { "text": "Does a quoted prevalence count the umbrella group or a particular subtype, in which population and observation period?", "kind": "measurement", "id": "versioned-concept-mapping-q02" } ] } ] } ] }, { "id": "diagnostic-evidence", "name": "Diagnostic evidence", "description": "Assess red-cell, clinical and molecular evidence without equating a suggestive observation with a diagnosis.", "rationale": "Acanthocytosis and neurological findings require interpretation together with subtype-specific evidence.", "layers": [ { "id": "red-cell-morphology", "name": "Red-cell morphology", "description": "Capture the technical and temporal context of acanthocyte observations.", "findings": [ { "id": "interpretable-acanthocyte-result", "name": "Interpretable acanthocyte result", "description": "Preserve the original result and method rather than reducing morphology to an unexplained positive or negative flag.", "questions": [ { "text": "What acanthocyte proportion was reported, using which preparation, counting method, specimen age and laboratory reference?", "kind": "measurement", "id": "interpretable-acanthocyte-result-q01" }, { "text": "How were acanthocytes distinguished from echinocytes or preparation artefacts, and does uncertainty justify laboratory review?", "kind": "action", "id": "interpretable-acanthocyte-result-q02" } ] } ] }, { "id": "subtype-confirmation", "name": "Subtype confirmation", "description": "Relate genetic and specialist evidence to a clearly stated diagnostic conclusion.", "findings": [ { "id": "molecular-and-clinical-concordance", "name": "Molecular and clinical concordance", "description": "Record why the available evidence supports, fails to resolve or contradicts the proposed subtype.", "questions": [ { "text": "Which gene findings, zygosity, assay limitations and dated variant interpretations support the proposed disease attribution?", "kind": "provenance", "id": "molecular-and-clinical-concordance-q01" }, { "text": "Which issuing body or expert source supplies the diagnostic framework and revision used, and what remains unresolved under it?", "kind": "definition", "id": "molecular-and-clinical-concordance-q02" }, { "text": "Could the neurological syndrome or acanthocytosis have an alternative explanation requiring separate assessment?", "kind": "boundary", "id": "molecular-and-clinical-concordance-q03" } ] } ] } ] }, { "id": "neurological-expression-and-course", "name": "Neurological expression and course", "description": "Represent the manifestation pattern and observed evolution relevant to recognition and function.", "rationale": "The umbrella label does not specify which neurological domains are affected or how they change.", "layers": [ { "id": "manifestation-pattern", "name": "Manifestation pattern", "description": "Record observed motor and non-motor features separately from inferred disease membership.", "findings": [ { "id": "domain-specific-phenotype", "name": "Domain-specific phenotype", "description": "Assess potentially relevant movement, bulbar, seizure, behavioural, cognitive and neuromuscular domains without presuming their presence.", "questions": [ { "text": "Which movement abnormalities, feeding-related oral movements, tongue or lip injuries, speech changes or swallowing difficulties are actually documented?", "kind": "measurement", "id": "domain-specific-phenotype-q01" }, { "text": "What evidence documents seizures, behavioural or cognitive change, weakness or peripheral nerve involvement, and which findings remain suspected?", "kind": "measurement", "id": "domain-specific-phenotype-q02" } ] } ] }, { "id": "trajectory-and-function", "name": "Trajectory and function", "description": "Distinguish observed progression from episodic or treatment-associated changes.", "findings": [ { "id": "dated-functional-change", "name": "Dated functional change", "description": "Use comparable observations and explicit milestones rather than imposing an unsupported universal stage.", "questions": [ { "text": "When did each manifestation begin, and how have mobility, communication, feeding and daily activities changed across dated assessments?", "kind": "measurement", "id": "dated-functional-change-q01" }, { "text": "If a stage or severity scale is assigned, which subtype, validation source and version justify its use?", "kind": "provenance", "id": "dated-functional-change-q02" } ] } ] } ] }, { "id": "systemic-and-inheritance-context", "name": "Systemic and inheritance context", "description": "Keep blood-group, systemic and familial implications conditional on the disease evidence.", "rationale": "These implications cannot safely be transferred indiscriminately between members of the group.", "layers": [ { "id": "mcleod-specific-context", "name": "McLeod-specific context", "description": "Connect relevant haematological and cardiac assessments to supported McLeod attribution.", "findings": [ { "id": "blood-group-and-cardiac-implications", "name": "Blood-group and cardiac implications", "description": "McLeod syndrome can involve cardiac disease as well as a distinctive blood-group phenotype; record specialist interpretation and assessed involvement. [GeneReviews: McLeod Neuroacanthocytosis Syndrome](https://www.ncbi.nlm.nih.gov/books/NBK1354/)", "questions": [ { "text": "What Kx/Kell findings and antibody results are documented, and has transfusion medicine recorded their compatibility implications?", "kind": "action", "id": "blood-group-and-cardiac-implications-q01" }, { "text": "What cardiac symptoms, investigations and surveillance recommendations are documented for the supported subtype?", "kind": "measurement", "id": "blood-group-and-cardiac-implications-q02" } ] } ] }, { "id": "familial-attribution", "name": "Familial attribution", "description": "Represent inheritance claims through the established subtype and molecular findings.", "findings": [ { "id": "supported-family-risk", "name": "Supported family risk", "description": "Keep a relative's risk, carrier status, molecular result and clinical manifestations distinct.", "questions": [ { "text": "Which subtype-specific inheritance interpretation is supported by the molecular result and available pedigree?", "kind": "provenance", "id": "supported-family-risk-q01" }, { "text": "What genetics review is needed before applying this interpretation to relatives or reproductive decisions?", "kind": "action", "id": "supported-family-risk-q02" } ] } ] } ] }, { "id": "care-decisions-and-evidence-limits", "name": "Care decisions and evidence limits", "description": "Turn documented manifestations and uncertainty into reviewable clinical assessment needs.", "rationale": "A useful model must support action while preserving the distinction between disease knowledge and an individual care decision.", "layers": [ { "id": "manifestation-led-assessment", "name": "Manifestation-led assessment", "description": "Identify review needs from current findings and the supported subtype.", "findings": [ { "id": "prioritised-specialist-review", "name": "Prioritised specialist review", "description": "Connect documented concerns to the responsible clinical service and the question requiring resolution.", "questions": [ { "text": "Do documented swallowing difficulties, weight change, seizures, injuries or cardiac symptoms require a change in assessment priority?", "kind": "action", "id": "prioritised-specialist-review-q01" }, { "text": "Which neurology, swallowing, nutrition, cardiology, haematology or genetics review would resolve the identified concern?", "kind": "action", "id": "prioritised-specialist-review-q02" } ] } ] }, { "id": "intervention-applicability", "name": "Intervention applicability", "description": "Evaluate proposed interventions against the actual subtype, target manifestation and evidence.", "findings": [ { "id": "bounded-treatment-claim", "name": "Bounded treatment claim", "description": "Separate a treatment claim from an individual prescription and distinguish symptomatic outcomes from claims about disease progression.", "questions": [ { "text": "For a proposed medicine, feeding intervention or deep brain stimulation, which subtype, target symptom, evidence source and publication date support applicability?", "kind": "provenance", "id": "bounded-treatment-claim-q01" }, { "text": "Which baseline, intended outcome, adverse effects and reassessment interval would allow the treating team to evaluate benefit?", "kind": "action", "id": "bounded-treatment-claim-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "The term has variable scope: distinguish the two core syndromes from historically broader groupings of neurological disorders with acanthocytosis.", "This is a recall-based description; no sources or current classification revisions were checked.", "Verify subtype-specific diagnostic criteria, ICD and SNOMED CT mappings, and population-specific prevalence before publication; no universal acanthocyte threshold is asserted." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "VPS13A disease, historically called chorea-acanthocytosis", "McLeod neuroacanthocytosis syndrome" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "OMIM", "value_or_pattern": "200150", "note": "Identifies chorea-acanthocytosis, now commonly called VPS13A disease; it does not identify the entire neuroacanthocytosis group." }, { "scheme": "HGNC gene symbols", "value_or_pattern": "VPS13A; XK", "note": "Genes associated with VPS13A disease and McLeod syndrome, respectively; these are gene identifiers, not interchangeable disease codes." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "A diagnostic grouping considered in patients with combinations of chorea, dystonia, psychiatric or cognitive changes, seizures, and peripheral neuromuscular abnormalities.", "Distinguishing the underlying disorder guides genetic counselling, family testing, and surveillance.", "Recognition of McLeod syndrome informs cardiac assessment and specialist transfusion planning." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Acanthocyte proportion in peripheral blood", "typical_range": "Variable and dependent on specimen preparation and examination method; a negative result does not exclude a core syndrome.", "unit": "% of examined red blood cells" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Excluding the diagnosis because a routine blood smear shows no acanthocytes.", "Treating acanthocytosis alone as diagnostic despite its occurrence in other disorders.", "Confusing acanthocytes with echinocytes or preparation artifacts.", "Missing dysphagia, aspiration risk, seizures, or self-injurious oral movements in affected patients.", "Missing cardiomyopathy, arrhythmias, or transfusion compatibility issues associated with McLeod syndrome." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Acanthocytosis", "difference": "A red-cell morphological finding that can occur without an inherited neurological syndrome." }, { "name": "Huntington disease", "difference": "An overlapping progressive movement and neuropsychiatric disorder distinguished by a pathogenic CAG expansion in HTT." }, { "name": "Abetalipoproteinemia", "difference": "Can cause acanthocytosis and neurological impairment through a lipid-transport disorder with fat malabsorption and vitamin deficiency; historically included in broader uses of neuroacanthocytosis." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of neuroacanthocytosis this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which contemporary authority should define the registry umbrella's membership, especially the status of historically associated lipid disorders, Huntington disease-like 2 and pantothenate kinase-associated neurodegeneration?", "Which current ICD-10, ICD-11 and SNOMED CT identifiers map to the umbrella and its constituent diseases in the intended jurisdiction?", "Which diagnostic frameworks and acanthocyte assessment methods should be adopted, and what are their limitations across subtypes and disease phases?", "What population- and year-specific prevalence estimates are sufficiently supported, and how much do ascertainment and subtype definitions affect them?", "Which longitudinal outcome measures, surveillance intervals and intervention evidence are validated for each subtype rather than extrapolated across the group?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 17, "questions": 28 } }